CXCL10 and neoplasm: Together, these findings demonstrate that targeted CXCL10 knock-in into tumour cells enhances tumoural immune infiltration, improves CAR T cell recruitment, and prolongs tumour control in vivo, supporting the therapeutic potential of tumour-intrinsic cytokine expression for strengthening adoptive cell therapy in solid tumours.